Related Experiment Video
Updated: Jul 2, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Hyperosmotic stress contributes to mouse colonic inflammation through the methylation of protein phosphatase 2A
Laurent Schwartz1, Mohammad Abolhassani, Mohammad Pooya
1Service de Radiothérapie Hôpital Pitié-Salpétrière, bd. de l'Hôpital, 75013 Paris, France. laurent.schwartz@polytechnique.edu
Abstract:
There are several reports suggesting hyperosmotic contents in the feces of patients suffering from inflammatory bowel disease (IBD). Previous works have documented that hyperosmolarity can cause inflammation attributable to methylation of the catalytic subunit of protein phosphatase 2A (PP2A) and subsequent NF-kappaB activation resulting in cytokine secretion. In this study, we demonstrate that dextran sulfate sodium (DSS) induces colitis due to hyperosmolarity and subsequent PP2A activation. Mice were randomized and fed with increased concentrations of DSS (0 mOsm, 175 mOsm, 300 mOsm, and 627 mOsm) for a duration of 3 wk or with hyperosmotic concentrations of DSS (627 mOsm) or mannitol (450 mOsm) for a duration of 12 wk. Long-term oral administration of hyposmotic DSS or mannitol had no demonstrable effect. Hyperosmotic DSS or mannitol produced a significant increase in colonic inflammation, as well as an increase in the weight of sacral lymph nodes and in serum amyloid A protein levels. Similar results were obtained through the ingestion of comparable osmolarities of mannitol. Hyperosmolarity induces the methylation of PP2A, nuclear p65 NF-kappaB activation. and cytokine secretion. The rectal instillation of okadaic acid, a well-known PP2A inhibitor, reverses the IBD. Short inhibiting RNAs (siRNAs) targeted toward PP2Ac reverse the effect of hyperosmotic DSS. The present study strongly suggests that DSS-induced chronic colitis is a consequence of the methylation of PP2Ac induced by hyperosmolarity.
Insights
Hyperosmolarity in the gut, such as from dextran sulfate sodium (DSS), causes inflammatory bowel disease (IBD) by activating protein phosphatase 2A (PP2A). Inhibiting PP2A can reverse this inflammation.
Area of Science:
- Gastroenterology
- Molecular Biology
- Immunology
Background:
- Inflammatory bowel disease (IBD) is linked to hyperosmotic fecal content.
- Hyperosmolarity is known to induce inflammation via protein phosphatase 2A (PP2A) methylation and NF-kappaB activation.
Purpose of the Study:
- To investigate the role of hyperosmolarity and PP2A activation in dextran sulfate sodium (DSS)-induced colitis.
- To explore potential therapeutic targets for DSS-induced chronic colitis.
Main Methods:
- Mice were administered varying concentrations of DSS or mannitol orally for 3 or 12 weeks.
- Assessed colonic inflammation, sacral lymph node weight, serum amyloid A levels.
- Investigated the effects of a PP2A inhibitor (okadaic acid) and siRNAs targeting PP2Ac.
Main Results:
- Hyperosmotic DSS and mannitol significantly increased colonic inflammation, lymph node weight, and serum amyloid A.
- Hyperosmolarity led to PP2A methylation, NF-kappaB activation, and cytokine secretion.
- Okadaic acid and PP2Ac-targeting siRNAs reversed DSS-induced colitis.
Conclusions:
- DSS-induced chronic colitis is caused by hyperosmolarity-induced methylation of PP2Ac.
- PP2A activation is a key mechanism in hyperosmolarity-driven gut inflammation.
- Targeting PP2A may offer a therapeutic strategy for IBD.
